HC Wainwright Has Bullish Forecast for Precigen Q3 Earnings

Precigen, Inc. (NASDAQ:PGEN) – Analysts at HC Wainwright lifted their Q3 2026 earnings per share estimates for Precigen in a research report issued to clients and investors on Thursday, March 26th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will earn $0.00 per share for the quarter, up from their prior estimate of ($0.01). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Precigen’s FY2027 earnings at $0.22 EPS, FY2028 earnings at $0.44 EPS, FY2029 earnings at $0.69 EPS and FY2030 earnings at $1.02 EPS.

A number of other research analysts also recently issued reports on the company. Citizens Jmp lifted their price target on Precigen from $8.00 to $9.00 and gave the company a “market outperform” rating in a report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a report on Thursday, January 22nd. Finally, Zacks Research raised Precigen from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Precigen currently has a consensus rating of “Hold” and an average target price of $9.50.

Precigen Trading Up 25.3%

NASDAQ:PGEN opened at $3.89 on Friday. The firm has a market cap of $1.37 billion, a P/E ratio of -2.90 and a beta of 1.10. The firm has a 50-day simple moving average of $4.10 and a 200-day simple moving average of $3.98. The company has a debt-to-equity ratio of 2.22, a quick ratio of 3.95 and a current ratio of 4.04. Precigen has a one year low of $1.11 and a one year high of $5.47.

Precigen (NASDAQ:PGEN) last posted its quarterly earnings results on Wednesday, March 25th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.09. The business had revenue of $4.57 million for the quarter, compared to the consensus estimate of $8.29 million. Precigen had a negative return on equity of 2,313.82% and a negative net margin of 2,588.21%.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of PGEN. NBC Securities Inc. acquired a new stake in Precigen in the 4th quarter worth about $38,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Precigen during the third quarter valued at approximately $39,000. Russell Investments Group Ltd. purchased a new position in shares of Precigen in the third quarter valued at approximately $41,000. Mason Investment Advisory Services Inc. purchased a new position in shares of Precigen in the fourth quarter valued at approximately $42,000. Finally, Abel Hall LLC acquired a new stake in shares of Precigen in the fourth quarter worth approximately $44,000. Institutional investors and hedge funds own 33.51% of the company’s stock.

Key Stories Impacting Precigen

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: PAPZIMEOS commercial momentum: Precigen reported PAPZIMEOS generated $3.4M in net product revenue in Q4 (partial quarter) and said demand picked up sharply into Q1; company has $100.4M in cash to fund operations toward a 2026 cash-flow breakeven target. Precigen Reports Full Year 2025 Financial Results and Business Updates
• Positive Sentiment: Company guidance and payer progress: Precigen expects Q1 revenue to exceed $18M as PAPZIMEOS launch accelerates with broad U.S. payer coverage; CMS assigned a permanent J‑code (J3404) effective Apr 1, which should streamline reimbursement. Precigen expects Q1 revenue to exceed $18M as PAPZIMEOS launch accelerates with broad U.S. payer coverage
• Positive Sentiment: Analyst upgrades and higher targets: Multiple firms raised price targets and ratings after the results (HC Wainwright to $10 buy; Citizens JMP to $9 market outperform), reflecting expectations for meaningful upside as the commercial rollout scales. These Analysts Boost Their Forecasts On Precigen Following Q4 Results
• Positive Sentiment: Bull thesis and modeled upside: A recent deep-dive bullish note highlights PAPZIMEOS’s blockbuster potential, models Q1 run-rate and payer traction, and produces a probability-weighted fair value (~$6.13–$7.01 per share) above current levels. Precigen: The Best Potential Blockbuster You’ve Never Heard Of (Your ENT Has)
• Neutral Sentiment: Earnings call and transcripts available: Management held its full-year 2025 call and provided operational color on commercial expansion and an open‑label redosing study; transcripts and call highlights are published. Precigen, Inc. (PGEN) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 revenue missed estimates: Reported EPS beat slightly (smaller loss) but Q4 revenue was $4.57M vs. consensus ~$8.29M; the company still shows deep negative margins and high leverage metrics, which are risks until commercial revenues scale. Precigen (PGEN) Q4 2025 Earnings / MarketBeat
• Negative Sentiment: Valuation and momentum caution: Coverage pieces note PGEN’s ~145% one‑year run, and some investors may view current gains as late-stage momentum, raising near-term valuation risk if launch cadence or reimbursement lags expectations. Is It Too Late To Consider Precigen (PGEN) After Its 145% One Year Surge?

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.